<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35023454</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5607</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>13</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Mini reviews in medicinal chemistry</Title><ISOAbbreviation>Mini Rev Med Chem</ISOAbbreviation></Journal><ArticleTitle>Aptamers Against COVID-19: An Untested Opportunity.</ArticleTitle><Pagination><StartPage>1708</StartPage><EndPage>1715</EndPage><MedlinePgn>1708-1715</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1389557522666220112094951</ELocationID><Abstract><AbstractText>Given the lack of success in the development of effective drugs to treat COVID-19, which show "game-changing" potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is the case for direct antivirals and anti-inflammatory drugs, both of which treat different phases of the disease. Aptamers are molecules that deliver different modes of action, allowing their effects to be bundled, which, when combined, support their therapeutic efficacy. In this minireview, we summarise the current activities in the development of aptamers for the treatment of COVID-19 and long-COVID. A special emphasis is placed on the capability of their multiple modes of action, which is a promising approach for treating complex diseases such as COVID-19.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haberland</LastName><ForeName>Annekathrin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Robert-R&#xf6;ssle-Str. 10, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mini Rev Med Chem</MedlineTA><NlmUniqueID>101094212</NlmUniqueID><ISSNLinking>1389-5575</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aptamer</Keyword><Keyword MajorTopicYN="N">BC 007</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long-COVID-19</Keyword><Keyword MajorTopicYN="N">multiple modes-of-action</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35023454</ArticleId><ArticleId IdType="pmc">PMC9896377</ArticleId><ArticleId IdType="doi">10.2174/1389557522666220112094951</ArticleId><ArticleId IdType="pii">MRMC-EPUB-120116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salway R.J., Silvestri D., Wei E.K., Bouton M. Using information technology to improve COVID-19 care at new york city health + hos-pitals. Health Aff. (Millwood) 2020;39(9):1601&#x2013;1604. doi: 10.1377/hlthaff.2020.00930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2020.00930</ArticleId><ArticleId IdType="pubmed">32673131</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohilla S. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19. Drug Dev. Res. 2021;82(1):12&#x2013;26. doi: 10.1002/ddr.21720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21720</ArticleId><ArticleId IdType="pubmed">33216381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F., Chen F., Ou Z., Fan Q., Tan X., Wang Y., Pan Y., Ke B., Li L., Guan Y., Mo X., Wang J., Wang J., Luo C., Wen X., Li M., Ren P., Ke C., Li J., Lei C., Tang X., Li F. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell. Mol. Immunol. 2020;17(11):1119&#x2013;1125. doi: 10.1038/s41423-020-00550-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00550-2</ArticleId><ArticleId IdType="pmc">PMC7546387</ArticleId><ArticleId IdType="pubmed">33037400</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozzo L., Longo L., Vitale D.C., Drago F. Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap. Front. Pharmacol. 2020;11:, 621934. doi: 10.3389/fphar.2020.621934.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.621934</ArticleId><ArticleId IdType="pmc">PMC7734326</ArticleId><ArticleId IdType="pubmed">33329008</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabalin I.G., Czub M.P., Majorek K.A., Brzezinski D., Grabowski M., Cooper D.R., Panasiuk M., Chruszcz M., Minor W. Molecu-lar determinants of vascular transport of dexamethasone in COVID-19 therapy. IUCrJ. 2020;7(Pt 6) doi: 10.1107/S2052252520012944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2052252520012944</ArticleId><ArticleId IdType="pmc">PMC7553145</ArticleId><ArticleId IdType="pubmed">33063792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422. doi: 10.1136/bmj.n2422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2422</ArticleId><ArticleId IdType="pubmed">34607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A., Chaguturu R. In: Chapter 3 - Holistic Drug Targeting. Innovative Approaches in Drug Discovery; Patwardhan, B. Chaguturu R., editor. Boston: Academic Press; 2017. pp. 65&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-801814-9.00003-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G., Wilson G., Hebbard L., Duan W., Liddle C., George J., Qiao L. Aptamers: A promising chemical antibody for cancer thera-py. Oncotarget. 2016;7(12):13446&#x2013;13463. doi: 10.18632/oncotarget.7178.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.7178</ArticleId><ArticleId IdType="pmc">PMC4924653</ArticleId><ArticleId IdType="pubmed">26863567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker W.O., Shum K.T., Tanner J.A. G-quadruplex DNA aptamers and their ligands: Structure, function and application. Curr. Pharm. Des. 2012;18(14):2014&#x2013;2026. doi: 10.2174/138161212799958477.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799958477</ArticleId><ArticleId IdType="pubmed">22376117</ArticleId></ArticleIdList></Reference><Reference><Citation>Behbahani M., Mohabatkar H., Hosseini B. In silico design of quadruplex aptamers against the spike protein of SARS-CoV-2. Info. Med. Unlocked. 2021;26:, 100757. doi: 10.1016/j.imu.2021.100757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imu.2021.100757</ArticleId><ArticleId IdType="pmc">PMC8514331</ArticleId><ArticleId IdType="pubmed">34664030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzuvor C. Rethinking aptamers as nanotheranostic tools for Sars-Cov-2 and Covid-19 infection. 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.20944/preprints202008.0353.v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Torabi R., Ranjbar R., Halaji M., Heiat M. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systema-tic review. Mol. Cell. Probes. 2020;53:, 101636. doi: 10.1016/j.mcp.2020.101636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2020.101636</ArticleId><ArticleId IdType="pmc">PMC7334654</ArticleId><ArticleId IdType="pubmed">32634550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T-H., Lee S-W. Aptamers for anti-viral therapeutics and diagnostics. Int. J. Mol. Sci. 2021;22(8):4168. doi: 10.3390/ijms22084168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084168</ArticleId><ArticleId IdType="pmc">PMC8074132</ArticleId><ArticleId IdType="pubmed">33920628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger A., de Jesus Santos A.P., de S&#xe1; V., Ulrich H., Wrenger C. Aptamer applications in emerging viral diseases. Pharmaceuticals (Basel) 2021;14(7):622. doi: 10.3390/ph14070622.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14070622</ArticleId><ArticleId IdType="pmc">PMC8308861</ArticleId><ArticleId IdType="pubmed">34203242</ArticleId></ArticleIdList></Reference><Reference><Citation>Musafia B., Oren-Banaroya R., Noiman S. Designing anti-influenza aptamers: Novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction. PLoS One. 2014;9(5):, e97696. doi: 10.1371/journal.pone.0097696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097696</ArticleId><ArticleId IdType="pmc">PMC4028238</ArticleId><ArticleId IdType="pubmed">24846127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bala J., Chinnapaiyan S., Dutta R.K., Unwalla H. Aptamers in HIV research diagnosis and therapy. RNA Biol. 2018;15(3):327&#x2013;337. doi: 10.1080/15476286.2017.1414131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2017.1414131</ArticleId><ArticleId IdType="pmc">PMC5927724</ArticleId><ArticleId IdType="pubmed">29431588</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchand C., Maddali K., M&#xe9;tifiot M., Pommier Y. HIV-1 IN inhibitors: 2010 update and perspectives. Curr. Top. Med. Chem. 2009;9(11):1016&#x2013;1037. doi: 10.2174/156802609789630910.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156802609789630910</ArticleId><ArticleId IdType="pmc">PMC2860603</ArticleId><ArticleId IdType="pubmed">19747122</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez V.M., Mart&#xed;n M.E., Fern&#xe1;ndez G., Garc&#xed;a-Sacrist&#xe1;n A. Use of aptamers as diagnostics tools and antiviral agents for human viruses. Pharmaceuticals (Basel) 2016;9(4):, E78. doi: 10.3390/ph9040078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph9040078</ArticleId><ArticleId IdType="pmc">PMC5198053</ArticleId><ArticleId IdType="pubmed">27999271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 2018;17(4):261&#x2013;279. doi: 10.1038/nrd.2017.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz A., Weber A., Bayin M., Breuers S., Fieberg V., Famulok M., Mayer G.A. SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection by an RBD-independent mechanism. Angew. Chem. Int. Ed. Engl. 2021;60(18):10279&#x2013;10285. doi: 10.1002/anie.202100316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202100316</ArticleId><ArticleId IdType="pmc">PMC8251191</ArticleId><ArticleId IdType="pubmed">33683787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock L.C., Griffin L.C., Latham J.A., Vermaas E.H., Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit hu-man thrombin. Nature. 1992;355(6360):564&#x2013;566. doi: 10.1038/355564a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/355564a0</ArticleId><ArticleId IdType="pubmed">1741036</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberland A., Holtzhauer M., Schlichtiger A., Bartel S., Schimke I., M&#xfc;ller J., Dandel M., Luppa P.B., Wallukat G. Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur. J. Pharmacol. 2016;789:37&#x2013;45. doi: 10.1016/j.ejphar.2016.06.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2016.06.061</ArticleId><ArticleId IdType="pubmed">27375076</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller J. The DNA-Based drug BC 007 neutralizes agonistically acting autoantibodies directed against G protein&#x2013;coupled Receptors suc-cessful mode of action demonstrated in clinical phase 1 trial. Chem. Today. 2019;37(2):65&#x2013;67.</Citation></Reference><Reference><Citation>Becker N-P., Haberland A., Wenzel K., G&#xf6;ttel P., Wallukat G., Davideit H., Schulze-Rothe S., H&#xf6;nicke A-S., Schimke I., Bartel S., Grossmann M., Sinn A., Iavarone L., Boergermann J.H., Prilliman K., Golor G., M&#xfc;ller J., Becker S., Three-Part A.A. Three-Part, randomised study to investigate the safety, Tolerability, Pharmacokinetics and Mode of action of BC 007, neutraliser of pathogenic auto-antibodies against G-Protein coupled receptors in healthy, young and elderly subjects. Clin. Drug Investig. 2020;40(5):433&#x2013;447. doi: 10.1007/s40261-020-00903-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-020-00903-9</ArticleId><ArticleId IdType="pmc">PMC7181550</ArticleId><ArticleId IdType="pubmed">32222912</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisshoff H., Krylova O., Nikolenko H., D&#xfc;ngen H-D., Dallmann A., Becker S., G&#xf6;ttel P., M&#xfc;ller J., Haberland A. Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins. Heliyon. 2020;6(11):, e05421. doi: 10.1016/j.heliyon.2020.e05421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e05421</ArticleId><ArticleId IdType="pmc">PMC7605794</ArticleId><ArticleId IdType="pubmed">33163683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang K.J., Lee N-R., Yeo W-S., Jeong Y-J., Kim D-E. Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem. Biophys. Res. Commun. 2008;366(3):738&#x2013;744. doi: 10.1016/j.bbrc.2007.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.12.020</ArticleId><ArticleId IdType="pmc">PMC7092905</ArticleId><ArticleId IdType="pubmed">18082623</ArticleId></ArticleIdList></Reference><Reference><Citation>Parashar N.C., Poddar J., Chakrabarti S., Parashar G. Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2. Infect. Genet. Evol. 2020;85:, 104497. doi: 10.1016/j.meegid.2020.104497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104497</ArticleId><ArticleId IdType="pmc">PMC7417262</ArticleId><ArticleId IdType="pubmed">32791240</ArticleId></ArticleIdList></Reference><Reference><Citation>Shum K.T., Tanner J.A. Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. ChemBioChem. 2008;9(18):3037&#x2013;3045. doi: 10.1002/cbic.200800491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.200800491</ArticleId><ArticleId IdType="pmc">PMC7161993</ArticleId><ArticleId IdType="pubmed">19031435</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., Kusov Y., Mutschall D., Tech S., Nagarajan K., Hilgenfeld R., Schmidt C.L. The &#x201c;SARS-unique domain&#x201d; (SUD) of SARS co-ronavirus is an oligo(G)-binding protein. Biochem. Biophys. Res. Commun. 2007;364(4):877&#x2013;882. doi: 10.1016/j.bbrc.2007.10.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.10.081</ArticleId><ArticleId IdType="pmc">PMC7092865</ArticleId><ArticleId IdType="pubmed">17976532</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., Vonrhein C., Smart O.S., Bricogne G., Bollati M., Kusov Y., Hansen G., Mesters J.R., Schmidt C.L., Hilgenfeld R. The SARS-unique domain (SUD) of SARS coronavirus contains two macrodomains that bind G-quadruplexes. PLoS Pathog. 2009;5(5):, e1000428. doi: 10.1371/journal.ppat.1000428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000428</ArticleId><ArticleId IdType="pmc">PMC2674928</ArticleId><ArticleId IdType="pubmed">19436709</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze P., Macaya R.F., Feigon J. Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J. Mol. Biol. 1994;235(5):1532&#x2013;1547. doi: 10.1006/jmbi.1994.1105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1994.1105</ArticleId><ArticleId IdType="pubmed">8107090</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo Krauss I., Napolitano V., Petraccone L., Troisi R., Spiridonova V., Mattia C.A., Sica F. Duplex/quadruplex oligonucleotides: Role of the duplex domain in the stabilization of a new generation of highly effective anti-thrombin aptamers. Int. J. Biol. Macromol. 2018;107(Pt B):1697&#x2013;1705. doi: 10.1016/j.ijbiomac.2017.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2017.10.033</ArticleId><ArticleId IdType="pubmed">29024684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikin O., D&#x2019;Antonio L., Bagga P.S. QGRS Mapper: A webbased server for predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res. 2006;34(Web Server issue):W676&#x2013;682. doi: 10.1093/nar/gkl253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl253</ArticleId><ArticleId IdType="pmc">PMC1538864</ArticleId><ArticleId IdType="pubmed">16845096</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Y., Girvan A.C., Casson L.K., Pierce W.M., Jr, Qian M., Thomas S.D., Bates P.J. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007;67(21):10491&#x2013;10500. doi: 10.1158/0008-5472.CAN-06-4206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-4206</ArticleId><ArticleId IdType="pubmed">17974993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugrinova I., Petrova M., Chalabi-Dchar M., Bouvet P. Multifaceted nucleolin protein and its molecular partners in oncogenesis. Adv. Protein Chem. Struct. Biol. 2018;111:133&#x2013;164. doi: 10.1016/bs.apcsb.2017.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.apcsb.2017.08.001</ArticleId><ArticleId IdType="pubmed">29459030</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm S., Lodmell J.S. C/D box snoRNAs in viral infections: RNA viruses use old dogs for new tricks. Noncoding RNA Res. 2019;4(2):46&#x2013;53. doi: 10.1016/j.ncrna.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncrna.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6533054</ArticleId><ArticleId IdType="pubmed">31193534</ArticleId></ArticleIdList></Reference><Reference><Citation>Girvan A.C., Teng Y., Casson L.K., Thomas S.D., J&#xfc;liger S., Ball M.W., Klein J.B., Pierce W.M., Jr, Barve S.S., Bates P.J. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nu-cleolin. Mol. Cancer Ther. 2006;5(7):1790&#x2013;1799. doi: 10.1158/1535-7163.MCT-05-0361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-05-0361</ArticleId><ArticleId IdType="pubmed">16891465</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari R., Khanna G., Kaushik D., Kuhad A. Divulging the intricacies of crosstalk between NF-Kb and Nrf2-Keap1 pathway in neu-rological complications of COVID-19. Mol. Neurobiol. 2021;58(7):3347&#x2013;3361. doi: 10.1007/s12035-021-02344-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02344-7</ArticleId><ArticleId IdType="pmc">PMC7938034</ArticleId><ArticleId IdType="pubmed">33683626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M., Zhang J., Wan H., Yan C., Xia F. rationally designed multivalent aptamers targeting cell surface for biomedical applications. ACS Appl. Mater. Interfaces. 2021;13(8):9369&#x2013;9389. doi: 10.1021/acsami.0c15644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.0c15644</ArticleId><ArticleId IdType="pubmed">33146988</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Wang Y-L., Wu J., Qi J., Zeng Z., Wan Q., Chen Z., Manandhar P., Cavener V.S., Boyle N.R., Fu X., Salazar E., Kuchipudi S.V., Kapur V., Zhang X., Umetani M., Sen M., Willson R.C., Chen S-H., Zu Y. Neutralizing aptamers Block S/RBD-ACE2 interacti-ons and prevent host cell infection. Angew. Chem. Int. Ed. Engl. 2021;60(18):10273&#x2013;10278. doi: 10.1002/anie.202100345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202100345</ArticleId><ArticleId IdType="pmc">PMC8250721</ArticleId><ArticleId IdType="pubmed">33684258</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Song J., Wei X., Huang M., Sun M., Zhu L., Lin B., Shen H., Zhu Z., Yang C. Discovery of aptamers targeting the receptor-binding domain of the SARS-CoV-2 spike glycoprotein. Anal. Chem. 2020;92(14):9895&#x2013;9900. doi: 10.1021/acs.analchem.0c01394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.0c01394</ArticleId><ArticleId IdType="pubmed">32551560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M., Liu S., Wei X., Wan S., Huang M., Song T., Lu Y., Weng X., Lin Z., Chen H., Song Y., Yang C. Aptamer blocking strategy inhibits SARS-CoV-2 virus infection. Angew. Chem. Int. Ed. Engl. 2021;60(18):10266&#x2013;10272. doi: 10.1002/anie.202100225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202100225</ArticleId><ArticleId IdType="pmc">PMC8014204</ArticleId><ArticleId IdType="pubmed">33561300</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N.K., Ray P., Carlin A.F., Magallanes C., Morgan S.C., Laurent L.C., Aronoff-Spencer E.S., Hall D.A. Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer. Biosens. Bioelectron. 2021;180:, 113111. doi: 10.1016/j.bios.2021.113111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2021.113111</ArticleId><ArticleId IdType="pmc">PMC7908832</ArticleId><ArticleId IdType="pubmed">33743492</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Li Z., Mohammed I., Zhao L., Wei W., Xiao H., Guo W., Zhao Y., Qu F., Huang Y. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1. Signal Transduct. Target. Ther. 2021;6(1):227. doi: 10.1038/s41392-021-00649-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00649-6</ArticleId><ArticleId IdType="pmc">PMC8190169</ArticleId><ArticleId IdType="pubmed">34112756</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Perez A.I., Labandeira C.M., Pedrosa M.A., Valenzuela R., Suarez-Quintanilla J.A., Cortes-Ayaso M., May&#xe1;n-Conesa P., Labandeira-Garcia J.L. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J. Autoimmun. 2021;122:, 102683. doi: 10.1016/j.jaut.2021.102683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102683</ArticleId><ArticleId IdType="pmc">PMC8193025</ArticleId><ArticleId IdType="pubmed">34144328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Hohberger B., Wenzel K., F&#xfc;rst J., Schulze-Rothe S., Wallukat A., H&#xf6;nicke A.S., M&#xfc;ller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 2021;4:, 100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B., Harrer T., Mardin C., Kruse F., Hoffmanns J., Rogge L., Heltmann F., Moritz M.F., Szweczxykowski C., Schotten-hamml J., Kr&#xe4;ter M., Bergua A., Zenkel M., Gie&#xdf;l A., Schl&#xf6;tzer-Schrehardt U., L&#xe4;mmer R., Herrmann M., Haberland A., G&#xf6;ttel P., M&#xfc;ller J., Wallukat G.  Neutralization of Autoantibodies Targeting G-Protein Coupled Receptors Improves Capillary Impairment and Fati-gue Symptoms after COVID-19 Infection. Rochester, NY: Social Science Research Network; 2021.  
 https://papers.ssrn.com/abstract=3879488
.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637609</ArticleId><ArticleId IdType="pubmed">34869451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P., Coppi A., Lucas C., Silva J., Oh J.E., Song E., Perotti E.S., Zheng N.S., Fischer S., Campbell M., Fournier J.B., Wyllie A.L., Vogels C.B.F., Ott I.M., Kalinich C.C., Petrone M.E., Watkins A.E., Dela Cruz C., Farhadian S.F., Schulz W.L., Ma S., Grubaugh N.D., Ko A.I., Iwasaki A., Ring A.M. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature. 2021;590(7844):29&#x2013;31. doi: 10.1038/d41586-021-00149-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00149-1</ArticleId><ArticleId IdType="pubmed">33469204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N., Antoniak S., Wolberg A.S., Kasthuri R., Key N.S. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler. Thromb. Vasc. Biol. 2020;40(9):2033&#x2013;2044. doi: 10.1161/ATVBAHA.120.314514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314514</ArticleId><ArticleId IdType="pmc">PMC7447001</ArticleId><ArticleId IdType="pubmed">32657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Talasaz A.H., Sadeghipour P., Kakavand H., Aghakouchakzadeh M., Kordzadeh-Kermani E., Van Tassell B.W., Gheymati A., Arian-nejad H., Hosseini S.H., Jamalkhani S., Sholzberg M., Monreal M., Jimenez D., Piazza G., Parikh S.A., Kirtane A.J., Eikelboom J.W., Connors J.M., Hunt B.J., Konstantinides S.V., Cushman M., Weitz J.I., Stone G.W., Krumholz H.M., Lip G.Y.H., Goldhaber S.Z., Bikdeli B. Recent randomized trials of antithrombotic therapy for patients with covid-19: jacc state-of-the-art review. J. Am. Coll. Cardiol. 2021;77(15):1903&#x2013;1921. doi: 10.1016/j.jacc.2021.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.02.035</ArticleId><ArticleId IdType="pmc">PMC7963001</ArticleId><ArticleId IdType="pubmed">33741176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennuni M.G., Renda G., Grisafi L., Rognoni A., Colombo C., Lio V., Foglietta M., Petrilli I., Pirisi M., Spinoni E., Azzolina D., Hayden E., Aimaretti G., Avanzi G.C., Bellan M., Cantaluppi V., Capponi A., Castello L.M., D&#x2019;Ardes D., Corte F.D., Gallina S., Krengli M., Malerba M., Pierdomenico S.D., Savoia P., Zeppegno P., Sainaghi P.P., Cipollone F., Patti G. Clinical outcome with diffe-rent doses of low-molecular-weight heparin in patients hospitalized for COVID-19. J. Thromb. Thrombolysis. 2021;52(3):782&#x2013;790. doi: 10.1007/s11239-021-02401-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02401-x</ArticleId><ArticleId IdType="pmc">PMC7919624</ArticleId><ArticleId IdType="pubmed">33649979</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Zhang X., Xiao Y., Gao T., Wang G., Wang Z., Zhang Z., Hu Y., Dong Q., Zhao S., Yu L., Zhang S., Li H., Li K., Chen W., Bian X., Mao Q., Cao C. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. MedRxiv. 2020 doi: 10.1101/2020.04.23.20076851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.23.20076851</ArticleId></ArticleIdList></Reference><Reference><Citation>Daviet F., Guervilly C., Baldesi O., Bernard-Guervilly F., Pilarczyk E., Genin A., Lefebvre L., Forel J.M., Papazian L., Camoin-Jau L. Heparin-Induced thrombocytopenia in severe COVID-19. Circulation. 2020;142(19):1875&#x2013;1877. doi: 10.1161/CIRCULATIONAHA.120.049015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049015</ArticleId><ArticleId IdType="pmc">PMC7643786</ArticleId><ArticleId IdType="pubmed">32990022</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X., Li H., Zhao L., Zhang Y., Liu Z. Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications. Biomed. Pharmacother. 2021;143:, 112232. doi: 10.1016/j.biopha.2021.112232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112232</ArticleId><ArticleId IdType="pubmed">34649356</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg J.E., Bambury R.M., Van Allen E.M., Drabkin H.A., Lara P.N., Jr, Harzstark A.L., Wagle N., Figlin R.A., Smith G.W., Garraway L.A., Choueiri T., Erlandsson F., Laber D.A. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metas-tatic renal cell carcinoma. Invest. New Drugs. 2014;32(1):178&#x2013;187. doi: 10.1007/s10637-013-0045-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-013-0045-6</ArticleId><ArticleId IdType="pmc">PMC4560460</ArticleId><ArticleId IdType="pubmed">24242861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>